Salarius Pharmaceuticals Receives FDA Clearance of SP3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in RelapsedRefractory NonHodgkin Lymphoma Patients

HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces U.S. Food and Drug Administration (FDA) clearance of the company’s investigational new drug (IND) application…Read More